Chargement de l’entreprise
Just reported
Q3 2026 results
From Clover Health Investments's results release of 4 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
759,3M $US
+53 % y/y
+2,2 % q/qGuided
—
No guide given
EPS, GAAP
Actual
0,01 $US
-80 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
6,4M $US
-77 % q/q
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue2,97B $US – 3B $US+55 % y/y Raised +0,8 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Clover Health Investments is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Healthcare Plans
Graded A or B and worth $2B or more: A first, then the largest.
CVSCVS Health Corp114,9B $USA
CIThe Cigna Group78,1B $USA
OSCROscar Health, Inc.9,9B $USA
HUMHumana Inc.53,3B $USB
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A- CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Construit à partir des documents déposés par Clover Health Investments, Corp. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
